Search research articles
Contact Us
Filters
Showing results (81-90 of 89) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 89 results.
European Journal of Gynaecological Oncology
|
June 8, 2000
Factors influencing period of time between negative second-look laparotomy and ovarian carcinoma recurrence. Multicenter study in Poland
J Markowska, J Wilkoszarska, J Emerich, et al.
British Journal of Cancer
|
November 17, 2004
TP53 status determines clinical significance of ERBB2 expression in ovarian cancer
J Kupryjańczyk, R Madry, J Plisiecka-Hałasa, et al.
Anticancer Research
|
September 2, 1999
Prognostic significance of CA 125 and TPS levels after chemotherapy in ovarian cancer patients
A van Dalen, J Favier, L Baumgartner, et al.
Anticancer Research
|
May 1, 2001
Serum levels of CA 125 and TPS during treatment of ovarian cancer
A Van Dalen, J Favier, L Baumgartner, et al.
European Journal of Gynaecological Oncology
|
January 27, 2010
Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up
A van Dalen, J Favier, E Hallensleben, et al.
Gynecologic Oncology
|
December 6, 2000
Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients
A van Dalen, J Favier, A Burges, et al.
ESMO Open
|
December 17, 2021
Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study
J A Ledermann, B Zurawski, F Raspagliesi, et al.
British Journal of Cancer
|
March 20, 2003
Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen
J Kupryjańczyk, T Szymańska, R Madry, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 11, 2003
P21WAF1, P27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens
J Plisiecka-Hałasa, G Karpińska, T Szymańska, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 89) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 89 results.
European Journal of Gynaecological Oncology
|
June 8, 2000
Factors influencing period of time between negative second-look laparotomy and ovarian carcinoma recurrence. Multicenter study in Poland
J Markowska, J Wilkoszarska, J Emerich, et al.
British Journal of Cancer
|
November 17, 2004
TP53 status determines clinical significance of ERBB2 expression in ovarian cancer
J Kupryjańczyk, R Madry, J Plisiecka-Hałasa, et al.
Anticancer Research
|
September 2, 1999
Prognostic significance of CA 125 and TPS levels after chemotherapy in ovarian cancer patients
A van Dalen, J Favier, L Baumgartner, et al.
Anticancer Research
|
May 1, 2001
Serum levels of CA 125 and TPS during treatment of ovarian cancer
A Van Dalen, J Favier, L Baumgartner, et al.
European Journal of Gynaecological Oncology
|
January 27, 2010
Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up
A van Dalen, J Favier, E Hallensleben, et al.
Gynecologic Oncology
|
December 6, 2000
Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients
A van Dalen, J Favier, A Burges, et al.
ESMO Open
|
December 17, 2021
Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study
J A Ledermann, B Zurawski, F Raspagliesi, et al.
British Journal of Cancer
|
March 20, 2003
Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen
J Kupryjańczyk, T Szymańska, R Madry, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 11, 2003
P21WAF1, P27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens
J Plisiecka-Hałasa, G Karpińska, T Szymańska, et al.
Page
of 9